Depression Studies

Thank you for your interest in our studies. We are currently conducting several studies in adults focusing on the use of psychedelics, combined with psychological support, as a potential new, effective, and safe treatment for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The study durations range from 16 weeks to one year.

All participants in our studies will receive a psychiatric evaluation, physical exam, and laboratory tests at no cost.

If you are interested in participating, please contact us.

Study Descriptions

  • Study1

    COMP005

    This nation-wide study is evaluating the safety and efficacy of a synthetic form of psilocybin for patients suffering from treatment-resistant depression (TRD). Participants will receive a single dose of psilocybin or placebo, in combination with psychological support. Participants must have previously tried antidepressants and experienced little relief from their depression symptoms.

  • Study2

    5-Me0-DMT

    This study, conducted globally, is investigating the efficacy and safety of three different dosages of a synthetic psychedelic nasal spray for patients with treatment-resistant depression (TRD). In addition to a single dose of the compound, participants will receive psychological support. Participants must have previously tried antidepressants with little relief from their depression symptoms.

  • Study3

    USONA 301

    This global study is evaluating the safety and efficacy of a synthetic form of psilocybin for patients currently suffering of major depressive disorder (MDD) with at least moderate symptom severity. Participants will receive a single dose of psilocybin (25mg or 5 mg), or placebo, in combination with psychosocial support.

Scroll to Top